Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma.
Preliminary experience with a clinical trial of immunotherapy for glioblastoma, by means of intratumoural injection of autologous lymphocytes (AL) mixed with low doses of human lymphoblastoid interferon (HLI) is presented. In two of twelve patients, a transient reduction of tumoural volume was obtained. Morphological studies showed that injected lymphocytes remain within the tumour, and suggest tumoural lysis due to activity of natural killer (NK) cells. Clinically no significant prolongation of survival time could be achieved and, as in other series, patients with additional radiation therapy survived longer. But the morphological findings suggest that immunotherapy carrying NK-cells to contact with tumoural cells might be useful in some patients with glioblastoma. Actually no explanation can be given why only two of our cases responded positively. Regarding the otherwise poor prognosis it seems justified to continue these studies.
Vaquero
J
J
Department of Neurosurgery, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain.
Martínez
R
R
Oya
S
S
Coca
S
S
Barbolla
L
L
Ramiro
J
J
Salazar
F G
FG
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D002648:Child; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000008:administration & dosage* / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
D007372:Interferons